S'abonner

A tryptophan metabolite of the skin microbiota attenuates inflammation in patients with atopic dermatitis through the aryl hydrocarbon receptor - 06/06/19

Doi : 10.1016/j.jaci.2018.11.036 
Jinlei Yu, MD a, , Yang Luo, MS b, , Zhenlai Zhu, MD a, , Yufeng Zhou, MD, PhD c, , Licheng Sun, MD c, Jixin Gao, MD, PhD a, Jinlv Sun, MD, PhD d, Gang Wang, MD, PhD a, Xu Yao, MD, PhD b, , Wei Li, MD, PhD a, e,
a Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China 
b Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China 
c Children's Hospital and Institute of Biomedical Sciences, Shanghai, China 
e Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China 
d Department of Allergy, Peking Union Hospital, Peking Union Medical College, Beijing, China 

Corresponding author: Wei Li, MD, PhD, Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. Current affiliation: Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, 200040, China.Department of DermatologyXijing HospitalFourth Military Medical UniversityXi'an710032ChinaXu Yao, MD, PhD, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, 12 Jiangwangmiao St, Nanjing 210042, China.Institute of DermatologyChinese Academy of Medical Sciences and Peking Union Medical College12 Jiangwangmiao StNanjing210042China

Abstract

Background

Previous studies have revealed significant alterations in the skin microbiota of patients with atopic dermatitis (AD) not only in diversity and composition but also in function, and the tryptophan (Trp) metabolic pathway is attenuated in the skin microbiota of patients with AD.

Objective

We sought to assess Trp metabolites on the skin surfaces of patients with AD and to explore the function of the microbial Trp metabolites in skin inflammation in patients with AD.

Methods

A gel-patch method was developed to collect metabolites on the skin surface, which were then assessed by using liquid chromatography–tandem mass spectrometry. A mouse model of calcipotriol (MC903)–induced AD-like dermatitis was used to evaluate the effects of microbial metabolites on AD, and aryl hydrocarbon receptor (AhR)–null mice and keratinocyte cultures were used to investigate the mechanism.

Results

Major microbial metabolites of Trp were detected on the skin surfaces of healthy subjects, and the level of indole-3-aldehyde (IAId), an indole derivative of Trp catabolism, was significantly lower in lesional and nonlesional skin of patients with AD than that of healthy subjects. IAId significantly attenuated skin inflammation in mice with MC903-induced AD-like dermatitis, and this effect was blocked by an AhR antagonist and abolished in AhR-null mice. Furthermore, IAId was found to inhibit the MC903-induced expression of thymic stromal lymphopoietin in keratinocytes in vivo and in vitro, which was mediated by binding of AhR to the thymic stromal lymphopoietin promoter.

Conclusion

IAId, a skin microbiota–derived Trp metabolite, negatively regulated skin inflammation in patients with AD, revealing that skin microbiota play a significant functional role in the pathogenesis of AD.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Key words : Atopic dermatitis, skin, microbiota, tryptophan, metabolites, indole-3-aldehyde, aryl hydrocarbon receptor, thymic stromal lymphopoietin

Abbreviations used : AD, AhR, AhRE, CHS, CYP1A1, DMSO, FACS, 5-HTP, IAA, IAId, IMQ, KYN, LC-MS/MS, OXA, SCFA, siRNA, Trp, TSLP


Plan


 Supported by the National Natural Science Foundation of China (81573038, 91642116, 81573045, and 31400782), the CAMS Innovation Fund for Medical Sciences (2016-I2M-1-005), the Natural Science Foundation of Jiangsu Province (BK20151066 and BK20170162), and the Milstein Medical Asian American Partnership Foundation. W.L. was founded by a Municipal Human Resources Development Program for Outstanding Leaders in Medical Disciplines in Shanghai (2017BR039).
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2018  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 143 - N° 6

P. 2108 - juin 2019 Retour au numéro
Article précédent Article précédent
  • Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases
  • Tali Czarnowicki, Helen He, Alexandra Leonard, Hyun Je Kim, Naoya Kameyama, Ana B. Pavel, Randall Li, Yeriel Estrada, Huei-Chi Wen, Grace W. Kimmel, Hee J. Kim, Margot Chima, Mark Lebwohl, James G. Krueger, Emma Guttman-Yassky
| Article suivant Article suivant
  • HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis
  • Nick Dand, Michael Duckworth, David Baudry, Alice Russell, Charles J. Curtis, Sang Hyuck Lee, Ian Evans, Kayleigh J. Mason, Ali Alsharqi, Gabrielle Becher, A. David Burden, Richard G. Goodwin, Kevin McKenna, Ruth Murphy, Gayathri K. Perera, Radu Rotarescu, Shyamal Wahie, Andrew Wright, Nick J. Reynolds, Richard B. Warren, Christopher E.M. Griffiths, Catherine H. Smith, Michael A. Simpson, Jonathan N. Barker, BADBIR Study Group ‡ MarilynBenhamSagairHussainBrianKirbyLindaLawsonKathleenMcElhoneAnthonyOrmerodCarolineOwen, BSTOP Study Group, PSORT Consortium § Michael R.BarnesPaolaDi MeglioRichardEmsleyAndreaEvansKatherinePayneDeborahStocken, Marilyn Benham, Sagair Hussain, Brian Kirby, Linda Lawson, Kathleen McElhone, Anthony Ormerod, Caroline Owen, Michael R. Barnes, Paola Di Meglio, Richard Emsley, Andrea Evans, Katherine Payne, Deborah Stocken

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.